ADPKD Mayo Classification — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Highest risk of rapid kidney growth and eGFR decline – strong candidate for Tolvaptan
The Mayo imaging classification (1A-1E) stratifies ADPKD patients by htTKV growth rate and risk of CKD progression. Class 1E represents the highest risk group with the most rapid kidney growth. These patients are the strongest candidates for Tolvaptan therapy (NICE TA877). The classification requires serial imaging to estimate growth trajectory. Class 1A-1B typically have slower progression and may not benefit as much from Tolvaptan.
Reference: Mayo Clinic ADPKD Classification; NICE TA877 2022